EVAUX
LABORATOIRES

Press Release

06/06/2017

EVAUX® announces the presentation of clinical study results on its product EVONAIL® - a hydrating nail solution - at ASCO, an international oncology conference. EVONAIL® is proven to be an efficient ambulatory nail solution to prevent or treat nail toxicities during chemotherapy.

Paris, June 6, 2017

EVAUX LABORATOIRES, a company specialized in dermatology care, announced today the presentation of a poster summarizing the scientific results of the product **EVONAIL®** - a hydrating nail solution shown to prevent and treat nail toxicities – at ASCO, the American Society of Clinical Oncology, which held its conference on June 2017 in Chicago, USA.

EVONAIL®, is the nail care solution the most prescribed in France for the prevention and treatment of nail damages resulting from oncology treatments.

The study conducted by Doctors i-Yeon Kim [1] Oh Nam Ok [1] Jeong-ju Seo [1] Soo-Hyeon Lee[2] Jin Seok Ahn [1] Young-Hyuck Im [1] and Yeon Hee Park [1] at ASCO 2017 displays the results of a randomized and controlled clinical trial on the product EVONAIL® for the prevention and treatment of docetaxel-induced onycholysis and other nail toxicities in breast cancer patients with neoadjuvant/adjuvant chemotherapy.

Docetaxel-induced onycholysis and other nail toxicities are typical side effects of anthracycline and taxane treatments. According to a recent metanalysis, 35% of patients treated by docetaxel and 44% of those treated by paclitaxel are affected [3]. This pathology is often associated with painful paronychia and decreasing quality of life.

Onycholysis is amplified by the exposure of ultraviolet rays. Despite the frequency and severity of symptoms, there are few effective treatments that exist, with the exception of one treatment by cryotherapy, which provides discomfort to patients and is found inconvenient, therefore it is seldom used in clinics.

EVAUX
LABORATOIRES

Comparative prevalence of onycholysis according to grades



The group of patients using the product **EVONAIL®** reduced their risk of nail toxicities by half.

70% of breast cancer patients can prevent the deterioration of their nails (grade 1 or 2 onycholysis) while following docetaxel chemotherapy.

"This study demonstrates that the prophylactic application of **EVONAIL®** significantly reduces the incidence of onycholysis (61.5% in the control group compared to 29.4% in the experimental group). Published in the revue "Breast Cancer Research Treatment", this study brings about the significant contribution of an effective, simple and safe solution that does not cause pain and is easy to use in ambulatory care to reduce the incidence of docetaxel-induced onycholysis".

Doctor Jean-François Chanez, scientific director of EVAUX Laboratoires

EVAUX
LABORATOIRES

ASCO ABSTRACTS HAVE BEEN PUBLISHED TO THE CONFERENCE'S WEBSITE: ABSTRACTS.ASCO.ORG
INFORMATION RELATIVE TO THE POSTER PRESENTATION IS AS FOLLOWS:

"A prospective randomized controlled trial of hydrating nail solution for prevention or treatment of onycholysis in breast cancer patients who received neoadjuvant/adjuvant docetaxel chemotherapy"

DATE
Saturday, June 3rd, 1:15-4:45pm local time

SESSION
patient and survivor care

SOUS-CATÉGORIE
Symptom Management/Supportive Care/Palliative Care
Abstract N°10108, Poster Table #97.

PURPOSE

The purpose of this study was to evaluate the efficacy of hydrating nail solution **EVONAIL®** for the prevention and treatment of docetaxel-induced onycholysis and nail toxicities.

METHOD

This study was a randomized, controlled study of **EVONAIL®** for the prevention or treatment of onycholysis in patients with docetaxel after doxorubicin plus cyclophosphamide.

In the experimental group, patients painted **EVONAIL®** on nails and periungual areas once a day until developing onycholysis grade 2 (the control group did not apply any solution). After grade 2 onycholysis development, patients applied **EVONAIL®** twice a day regardless of being in the experimental or control group.

The primary endpoints were the incidence of grade 2 onycholysis and recovery rate from grade 2 onycholysis.

RESULTS

From August 2015 to May 2016, 103 patients were enrolled and completed this study. Of these, 25 cases of grade 1 and 22 cases of grade 2 onycholysis were observed. Prophylactic application of **EVONAIL®** resulted in a statistically significant reduction of grade 2 onycholysis compared to controls (13.7% compared to 28.8%, P = 0.034) and all grade onycholysis was also significantly lower in the experimental group (29.4% compared to 61.5%, P = 0.001), with a difference statistically significant in favor of the group **EVONAIL®**.

Other criteria evaluated included the delayed development of onycholysis (grade 2 and grade 1+2) represented by cycles of docetaxel chemotherapy, knowing that the protocol called for 4 cycles (one cycle represents 3 weeks between two sessions of docetaxel chemotherapy).

The delayed development of grade 2 onycholysis is 3.78 cycles for the experimental group, which is higher than for the control group (3.33 cycles). The difference is statistically significant (p=0.034) in favor of the experimental group treated with **EVONAIL®**.

Furthermore, the delayed development of grade 1+2 onycholysis is 3.59 cycles for the experimental group and 2.83 cycles for the control group. The difference is statistically significant (p=0.001). Thus, treatment with **EVONAIL®** clearly prolongs the delayed development of onycholysis.

In the 13 patients who developed grade 2 onycholysis before their last visit, regardless of whether they were in the experimental or control group, the application of **EVONAIL®** twice a day allowed for 6 of 13 patients (46.2%) to return to a less severe grade of onycholysis (grade 1 or 0).

CONCLUSION

Hydrating nail solution **EVONAIL®**, used for preventative purposes at the start of docetaxel chemotherapy, significantly reduces the incidence of onycholsis induced by this taxane in breast cancer patients.

1. *Ji-Yeon Kim et Oh Nam Ok: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea*
2. *Pfizer Pharmaceuticals Korea Limited, Seoul 04631, Korea*

3. *8. Minisini AM, Tosti A, Sobrero AF, Mansutti M, Piraccini BM, Sacco C, Puglisi F (2003) Taxane-induced nail changes: incidence, clinical presentation and outcome. Ann Oncol 14:333–337*

ABOUT EVONAIL®

EVONAIL® is sold in pharmacies
Transparent hydrating nail solution, with UVA/UVB filter
BOTTLED PRESENTATION 15ML WITH BRUSH
CODE ACL 3760031691079
CODE CNK 3145-752

Public recommended price 19.99 €

ABOUT US

EVAUX, French laboratory of dermatology, focuses its expertise in dermo-cosmetic care based on the properties of the hyperthermal water of Evaux-Les-Bains.

Its experience was built with patients suffering from skin and mucus secondary effects induced by chemotherapy and radiotherapy. This is one of the most demanding areas for dermo-cosmetic products.

Many medical evaluations have confirmed the efficacy of **EVAUX®**'s dermo-cosmetic products. **EVAUX®** products are sold in pharmacies and other specialized stores.

WEBSITE
www.evauxlaboratoires.com
info@evauxlaboratoires.com